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ABSTRACT
Most brain insulin comes from the pancreas
and is taken up by the brain by what appears to
be a receptor-based carrier. Type 2 diabetes
animal models associated with insulin resistance
show reduced insulin brain uptake and content.
Recent data point to changes in the insulin re-
ceptor cascade in obesity-related insulin resis-
tance, suggesting that brain insulin receptors
also become less sensitive to insulin, which
could reduce synaptic plasticity. Insulin trans-
port to the brain is reduced in aging and in
some animal models of type 2 diabetes; brain
insulin resistance may be present as well. Studies
examining the effect of the hyperinsulinic clamp
or intranasal insulin on cognitive function have
found a small but consistent improvement in
memory and changes in brain neuroelectric
parameters in evoked brain potentials con-
sistent with improved attention or memory
processing. These effects appear to be due to
raised brain insulin levels. Peripheral levels of
Insulin Growth Factor-I (IGF-I) are associated
with glucose regulation and influence glucose
disposal. There is some indication that reduced
sensitivity to insulin or IGF-I in the brain, as
observed in aging, obesity, and diabetes, decreases
the clearance of A[ amyloid. Such a decrease
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involves the insulin receptor cascade and can
also increase amyloid toxicity. Insulin and
IGF-I may modulate brain levels of insulin
degrading enzyme, which would also lead to an
accumulation ofA[ amyloid.
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INTRODUCTION
Over the last few years, there has been a re-
evaluation of the role of insulin and insulin growth
factors in brain functions. This re-evaluation has
been driven by a number of observations and
hypotheses that encompass the control of feeding
and adiposity, the impact of diabetes on the brain
and more recently, the interactions among insulin,
diabetes, Alzheimer’s disease, and amyloid depo-
sition. Several recent reviews have addressed the
role of brain insulin in the control of metabolism
and food intake (Gerozissis 2003. Porte et al.,
2005). Among several recent reports that support
such a role of insulin is the demonstration that
mice with conditional knockout of insulin
receptors in the brain are overweight, insulin
resistant, and glucose intolerant (Bruning et al.,
2000). Furthermore, blockade of hypothalamic
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insulin receptors by antisense oligonucleotides
produced hyperphagia, insulin resistance, and
weight increase (Obici et al., 2002). These
examples clearly’show that the brain insulin plays
an important role in feeding, peripheral metabo-
lism, and weight regulation. Recent evidence of a
down-regulation of brain insulin receptors in
obesity and diabetes suggest that insulin resistance
may also involve the brain (Mielke, 2005).
The aim of this review is to put together
various recent data that describe the possible role
of insulin, insulin receptors, and insulin growth
factors in learning and memory. The role of
insulin-related peptides is examined in the context
of aging, diabetes, and Alzheimer’s disease The
general hypotheses that are entertained in this
review are that
1. type 2 diabetes and obesity lead to insulin
resistance in the brain,
2. insulin resistance leads to cognitive impair-
ments in older diabetic patients and
3. insulin resistance increase amyloid deposition
in Alzheimer’s disease patients.
We first examine what is known about insulin’s
access to the brain and the impact of diabetes on
the transfer of insulin from blood to the brain. We
then present a brief summary of the results of
studies that examined the interactions between
diabetes, aging, and brain with reference to recent
reviews for an in-depth analysis of the neuro-
cognitive deficits in type 2 diabetes (Awad et al.,
2004; Messier, 2003; Messier et al., 2004).
Following this, we review studies that have tested
the ability of insulin to modulate brain functions
with a particular attention to learning and memory.
For an in-depth review of the role of insulin in
metabolism, feeding, and weight control, the
reader can consult several excellent reviews
(Gerozissis 2003. Porte et al., 2005. Woods, et al.,
2003). Because insulin and insulin growth factor
(IGF-I) partially share receptor activity and
interact under certain circumstances, we briefly
discuss several aspects of IGF-I in the adult and
the aging brain. Finally, we examine the interaction
of insulin and IGF-I with amyloid deposition and
processing as a possible mechanism in the dele-
terious effect of diabetes on Alzheimer’s disease
progression. We now turn to the examination of
the source of insulin in the brain.
INSULIN TRANSPORT THROUGH THE BLOOD-
BRAIN BARRIER
As discussed by Banks (2004), the nature of
insulin resistance in the brain remains unclear. In
the periphery, most insulin resistance is associated
with receptor or post-receptor effects in specific
tissues. In the brain, insulin resistance can
manifest itself through changes in brain insulin
uptake and by changes in the insulin receptor
function as well. To understand these changes, we
will briefly review what is known about the
transport of insulin through the blood-brain barrier.
The mechanisms by which insulin gains access
to the CNS have recently been reviewed (Banks
2004). Although insulin and its receptors are widely
spread throughout the brain (Dore et al., 1997.
Schulingkamp et al., 2000. Zhao et al., 1999),
apparently no significant insulin synthesis occurs
in the CNS (Woodset et a!., 2003). However, this
conclusion has to be tempered by the presence of
insulin mRNA in the brain and the possibility of
restricted insulin synthesis in the brain (Devaskar
et al., 1994). Most insulin is now thought to enter
the brain through a receptor-based, saturable trans-
porter that is largely saturated by serum levels of
insulin that do not induce hypoglycemia (Banks et
al., 1997a-c). Transport of insulin in the brain is
highest in the olfactory bulb (8 times that found in
the brain as a whole) followed by the pons,
medulla, and hypothalamus (Banks et al., 1999).
This level is consistent with the observation that
the olfactory bulb has the highest concentration of
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Evidence also suggests that insulin is released
in the hypothalamic extracellular space in
anticipation of a scheduled meal in rats. Such
insulin release is independent of blood insulin
levels, showing that certain brain regions can
release insulin in relation to a learned association
(Orosco et al., 1995). Additionally, a microdialysis
study showed that intra-hypothalamic infusion of
glucose increases extracellular insulin and that
aging and obesity significantly reduce the glucose-
mediated insulin release (Gerozissis et al., 2001).
Thus, elevations in blood insulin levels will
likely have different effects on different brain
regions at different concentrations, owing to the
disparity in insulin uptake into the brain. It is
likely that in brain areas where insulin uptake is
greatest, insulin could have regulatory effects
whereas in areas where uptake is smaller and
saturates at lower concentrations, insulin may .have
other effects, perhaps linked to a neurotrophic
action.
Therefore, any theories involving brain insulin
resistance will have to take into account not only
the regional variations in transport mechanisms but
also the concentrations of insulin and insulin
receptors in the brain. As a result, insulin
resistance in the brain could be due to changes in
the receptor-based insulin carrier that would lead
to reduced access of insulin to the brain or could
be due to changes in insulin receptor function
within the brain. One also has to take into account
the large variations in blood insulin levels that
follow ingestion of food and the feedback-related
inhibition of insulin transport during hyper-
glycemia. We now turn to the effect of diabetes
and aging on insulin transport and receptor
function.
Hyperglycemia (in normal animals), obesity,
and obesity-induced diabetes (in Zucker rats)
decrease insulin transport into the brain (Banks et
al., 1997a-b. Baskin et al., 1985. Kaiyala et al.,
2000). Consistent with decreased insulin transport,
obese Zucker rats have reduced brain levels of
insulin (Baskin et al., 1985). However, in strepto-
zotocin- or alloxan-induced diabetes, an increase
in insulin transport to the brain occurs that is
associated with the very low systemic insulin
levels in these models. Such low levels of insulin
result from the destruction of pancreatic beta cells.
In animals, insulin receptors are highly expressed
during development but decline during aging
(Zhao et al., 1999). One human post-mortem study
found that brain insulin, c-peptide, and insulin
receptors are reduced in older individuals (Frolich
et al., 1998).
Few studies have directly addressed the
hypothesis of brain insulin resistance. In a model
of metabolic syndrome (fructose-fed hamsters),
which leads to obesity and impaired glucose
tolerance, a downregulation of neural insulin
signaling was noted, as measured by the stimulated
tyrosine phosphorylation of the insulin receptor.
The downregulation was accompanied by a reduced
insulin-mediated long-term depression (LTD),
although no change occurred in the presynapti-
cally-mediated paired-pulse facilitation or in the
expression of LTP, indicating normal hippocampal
electrical activity. Thus, the establishment of
neural insulin resistance leads to a reduction of
insulin-induced changes in neural activity (Mielke
et al., 2005). Other reports that identified the
presence of insulin receptors in post-synaptic
densities (Abbott et al., 1999) and showed that
insulin can rapidly recruit GABAA receptors from
the intracellular pool to the post-synaptic domain,
suggesting a role for insulin in neural plasticity
(Wan et al., 1997). Similarly, insulin has been
shown to facilitate clathrin-mediated internalization
of AMPA receptors, causing a form of long-term
depression (Ahmadian et al., 2004). Also, insulin
inhibits hippocampal pyramidal neurons in isolated
brain slices at doses consistent with the presence
of high affinity binding sites for insulin in the
hippocampus (Palovick et al., 1984).
A recent study examined the effect of water
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the hippocampus of rats (Zhao et al., 1999). The
authors found (a) an upregulation of insulin receptor
mRNA in the CA1 and dentate gyrus of the
hippocampus, (b) an increased accumulation of
insulin receptor protein in the hippocampal crude
synaptic membrane fraction, and (c)a decrease in
the cytosolic fraction. This result suggests that
insulin receptors may be recruited to the synaptic
membrane following neuronal activation. In the
CA1 pyramidal neurons, changes in the distribu-
tion pattern of IR in particular cellular compart-
ments, such as the nucleus and dendritic regions,
were observed only in trained animals.
Mice with conditional inactivation of the
insulin receptor gene (brain/neuron specific knock-
out) have a complete loss of insulin-mediated
inhibition of neuronal apoptosis (and also a partial
inhibition of the IGF-I induced inhibition of
apoptosis, suggesting that the anti-apoptosis effect
of IGF-I may be partly mediated by insulin
receptor activation). However, these knockout
mice showed no deficiencies in learning and
memory and no difference in cerebral metabolism
as measured by 18F-FDG micro-PET. Although
Tau phosphorylation was increased, the increase
was not accompanied by increased neurofibrillary
tangles up to 18 months of age (Schubert et al.,
2004).
In summary, brain insulin, most of which
comes from the pancreas, is taken up by the brain
by what appears to be a receptor-based carrier.
Moreover, insulin is transported at various rates
through the blood-brain barrier to different brain
regions. Type 2 diabetes animal models, which are
associated with insulin resistance, show a reduced
uptake of insulin to the brain. Recent data point to
changes in the insulin receptor cascade in obesity-
related insulin resistance, suggesting that brain
insulin receptors also undergo changes similar to
those observed in the periphery. Finally, insulin
appears to modulate the membrane inclusion of
GABA and AMPA receptors, suggesting a role in
synaptic plasticity. The absence of insulin receptors
in the brain of conditional knockout mice does not
lead to any major deficit in learning and memory
This observation suggests that insulin and insulin
receptors have modulatory roles and their absence
can be compensated by other mechanisms. We
now turn to the various studies that have tried to
link insulin to memory and cognitive functions in
animals and humans.
Diabetes, aging, and the brain
A number of recent reviews have examined the
impact of diabetes on brain functions and the
possible link between diabetes and dementia
(Awad et al., 2002. Messier, 2003. Messier et al.,
2004. Strachan et al., 1997). The conclusions were
that (a)type 2 diabetes is associated with an
increased incidence of cognitive decline, particu-
larly in patients older than 70 years, and (b)that
diabetes appears to be a significant risk factor for
vascular dementia and Alzheimer’s disease.
Several studies have also linked diabetes with
brain atrophy. A Japanese MRI study found that
brain atrophy was 40,6 more frequent in diabetic
patients than in control participants, even though
no difference in vascular pathology occurred, as
revealed by the MRI (Araki et al., 1994). Similar
findings were obtained in a study in the Nether-
lands showing that the volumes of the amygdala
and hippocampus, two important structures for
memory processing, were reduced in diabetic
patients, regardless of vascular pathology (den
Heijer et al., 2003). A smaller study also found a
relation between an indirect measure of temporal
lobe volume and fasting blood glucose in diabetic
patients with a smaller temporal volume associated
with drug-treated diabetic patients compared with
diet-treated ones (Soininen et al., 1992). Finally, in
normal aged humans, memory and hippocampal
volume were found to be correlated to measures of
glucose tolerance (Convit et al., 2003). Taken
together, these studies suggest that the brain may
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periphery, and a number of recent studies have
addressed the role of insulin on cognitive
functions.
Another way to determine whether type 2
diabetes is associated with cognitive deficits is to
evaluate the long-term effects Of diabetes on
cognitive function and whether changes over time
are observable in repeated-measures designs.
Longitudinal studies allow for such an assessment
and limit the between-subjects variability observed
in cross-sectional studies.
Two recent longitudinal studies have been
conducted to evaluate the relation between cognitive
decline and type 2 diabetes. Gregg et al. (2000)
compared the performance of 682 diabetic, women
(mean duration of type 2 diabetes 10.2 years. SD
9.5 years) to the performance of 8997 age-
matched women (mean age 72 years) who were
assessed on two occasions: at baseline and 3 to 6
years following baseline assessment. Variables
such as age, education, depression, hypertension,
and cardiovascular disease were methodologically
controlled. The neuropsychological assessment
included a modified version of the Mini-Mental
State Examination as a brief cognitive screening
measure, a psychomotor speed test, and a measure
of frontal lobe/executive function. The results of
this study revealed an increased odds of major
cognitive decline in type 2 diabetic patients
(defined as the greatest 10
th percentile reduction in
performance from initial to follow-up score) on the
psychomotor speed test and the measure of frontal
lobe/executive function--Digit Symbol test
(Wechsler 1981) and Trails B test (Spreen &
Strauss 1998).
A second longitudinal study compared the
performance of 55 type 2 diabetes participants
with the performance of 103 participants with
impaired fasting glucose and 768 age-matched
controls (mean age 65 years) on several neuro-
psychological tests. These tests included the Mini-
Mental State Examination, as well as measures of
verbal and visual memory, facial recognition,
executive function, motor function, arithmetic
ability, processing speed, and logical reasoning
(Fontbonne et al., 2001). The authors controlled
for age, gender, education, depression, hyper-
tension, and body mass index. They reported,
however, that diabetic participants had higher
levels of triglycerides, as well as lower levels of
total cholesterol and HDL cholesterol compared
with controls. The authors concluded that the odds
ratios for ’serious worsening’ were greater than 2
for measures of verbal memory, facial recognition,
processing speed, and motor function. Serious
worsening is defined as a change in memory
scores down to the lowest 15% of the distribution
of the observed changes for the whole sample.
Taken together, these longitudinal studies suggest
that participants with type 2 diabetes are at higher
risk for cognitive decline compared with age-
matched controls.
The findings of these longitudinal studies are
further substantiated by studies evaluating risk of
co-existence of diabetes and dementia (reviewed in
Messier, 2003). Some studies evaluating the co-
existence of these two diseases demonstrated a
moderate association between diabetes and
Alzheimer’s disease, with odds ratios ranging from
1.3 to 1.9 (Brayne et al., 1998. Ott et al., 1996. Ott
et al., 1999. Peila et al., 2002). This finding has
not been consistently observed, however, as other
studies have not reported such associations (Odds
ratios ranging from 1.0 to 1.3. (Curb et al., 1999.
Leibson et al., 1997. Luchsinger et al., 2001).
Recently, Peila et al. (2002) demonstrated that the
odds ratio for the co-existence of diabetes and
Alzheimer’s disease significantly increased only
for subjects with the ApoE4 allele. Post-mortem
examination of these subjects revealed that
Alzheimer’s patients who were diabetic had an
increased number of infarcts and that the ApoE4
allele was associated with increased neuro-
fibrillar tangles in the hippocampus and cortex,
as well as increased cerebral amyloid angiopathy.
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disease was associated with hyperinsulinemia
(Bucht et al., 1983. Craft et al., 1993. Craft et al.,
1996. 1998), others did not (Fujisawa et al., 1991.
Kilander et al., 1993). Two studies found that
compared with ApoE2 bearers, bearers of the
ApoE4 allele tend to have lower insulin levels
(Craft et al., 1998. Gonzalez et al., 1999).
The relation between diabetes and Alzheimer’s
disease remains unclear, but could be mediated by
the insulin-degrading enzyme (IDE), which also
degrades beta-amyloid protein. Given that insulin
competes with beta-amyloid for the insulin-
degrading enzyme, it has been proposed that in
certain cases, Alzheimer’s disease amyloid
deposition can be increased by excessive levels of
insulin (Cook et al., 2003. Craft et al., 2000. Ling
et al., 2002). However, there is no indication that
high levels of insulin or diabetes, as such,
independently produce amyloid deposition of
neurofibrillary tangles (Heitner & Dickson 1997.
Peila et al., 2002), suggesting that diabetes is not a
cause of Alzheimer’s pathology. Rather, insulin
may further aggravate the pathologies already
present in Alzheimer’s patients. This possibility
will be discussed further below.
In the preceding sections, we have examined
the possibility that the insulin resistance found in
muscle and fat tissues in people with peripheral
insulin resistance and type 2 diabetes may also be
found for insulin receptors in the brain. Together,
the observations that suggest that insulin transport
to the brain is reduced in aging, and in some
animal models of type 2 diabetes, has led to the
proposal that stimulation of the brain’s insulin
receptors could facilitate brain function and, more
precisely, learning and memory. This hypothesis
has been tested using several methodologies, as
described in the next section.
Effect of insulin on cognitive functions
Very few studies have shown a beneficial
effect of peripheral insulin injections on brain
functions owing to the hypoglycemic action of
insulin and the deleterious effect of hypoglycemia
on brain function (Kopf & Baratti 1995, 1999).
One experiment, however, showed that insulin
injected in conjunction with glucose improved
memory in rats (Messier & White 1987). Similarly,
the peripheral injection of small doses of insulin
reversed the amnesia produced by scopolamine in
a food-motivated operant task (Blanchard &
Duncan 1997. Messier & Destrade 1994). Intra-
cerebroventricular injection of insulin was shown
to improve the performance on an avoidance task
(Park et al., 1995), although no effect on memory
was found following intrahippocampal insulin
injection in rats (Paulus et al., 2005).
The observations that insulin, insulin receptors,
and C-peptide levels in cerebral spinal fluid (CSF)
appear to be reduced in aging, (Frolich et al., 1998)
along with the finding that Alzheimer’s patients
have lower levels of insulin in the CSF (Craft et
al., 1998) suggest impaired transport of insulin
into the CSF. The results of these studies have
prompted several studies examining the effect of
insulin in young and old persons.
The effect of insulin on brain function in
humans has been studied using two experimental
protocols. In the first, the hyperinsulinemic clamp
procedure, increased blood insulin levels are main-
tained while glucose is infused intravenously to
keep blood glucose levels close to normal fasting
levels. One study showed that verbal memory is
improved in Alzheimer’s patients but not in normal
age-matched controls during the hyperinsulinemic
clamp procedure (Craft et al., 1996).
A second study that also used the hyper-
insulinemic clamp showed that insulin improves
the memory of younger patients for emotional
words, and also produces changes in the evoked
potentials P300 latencies, suggesting an influence
of insulin on attentional-cognitive functions (Kern
et al., 2001). Another study examined the impact
of different blood insulin levels using the
hyperinsulinemic clamp in Alzheimer patients andINSULIN AND GLUCOSE TRANSPORTERS 317
aged-matched controls. Patients homozygotic for
the APOE4 genotype and healthy controls had
better recall at the low insulin levels (150 pmol/L),
whereas patients with no APOE4 alleles had better
recall at higher insulin levels (219 pmol/L) (Craft
et al., 2003), suggesting a dose-response curve
specific for each population.
In an FDG-PET study using the euglycemic
clamp, the effect of insulin together with a glucose
infusion produced an increase in cerebral glucose
uptake (Bingham et al., 2002). In this study,
somatostatin was given to suppress endogenous
insulin secretion, and intravenous glucose was used
to keep blood glucose levels at 5 mmol/L. Little
glucose was infused in the control condition, but
an average of 292.45 mg/kg of glucose was infused
to keep glucose levels stable during the insulin
infusion. As a result, the study actually demon-
strated the combined effect of exogenous insulin
and glucose on cerebral glucose uptake. This
effect may be exerted either through a metabolic
effect of insulin on brain glucose uptake or
through a neuronal activation produced by the
combined glucose-insulin infusion.
Another approach that has been taken to
introduce insulin into the brain is intranasal admin-
istration. Experimental studies using mice (Giz-
urarson et al., 1995), rats (Thome, et al., 2004) or
monkeys (Anand et al., 1974. Gopinath et al.,
1978) showed that peptides delivered into the
nasal cavity via, or close to, the olfactory epi-
thelium are transported into the brain within 10 to
15 minutes. Various mechanisms are thought to
allow peptides to enter the brain through the
intranasal route, although the precise mechanisms
have not been elucidated. The mechanism most
likely to provide rapid entry into the brain involves
an extraneuronal pathway through perineural
channels that deliver peptides to the parenchyma
and/or the CSF (Frey, 2002).
Another possible route is along the trigeminal
neural pathway (Thome et al., 2004). A detailed
analysis of the transfer of IGF-I from the nose to
the brain showed significant IGF-I concentrations
in most brain regions after 30 min, with olfactory
structures having the highest concentration (Thome
et al., 2004). Detectable IGF-I concentrations were
found in the hippocampus, midbrain, cerebellum,
medulla, and cervical spinal cord, showing a wide
distribution in the brain 30 min after intranasal
administration. A double-blind crossover study
looking at the safety of intranasal insulin revealed
no adverse effects after three weeks of daily 60IU
intranasal insulin administration (Kupila et al.,
2003). More-over, no effect on blood glucose
levels was found, indicating that intranasal insulin
does not induce hypoglycemia.
A study examined the effect of 20IU of insulin
administered in the nasal cavities every 15 min for
2.5 h in adult male volunteers of normal weight
(Kern et al., 1999). At 30 min and 2 h, an EEG was
recorded to assess auditory-evoked brain potentials.
Baseline-to-peak amplitudes of the N (but not P2)
component of auditory-evoked brain potentials
were reduced during insulin infusions for the central
(Cz) and parietal (Pz) locations. The amplitude of
the P3 component was also reduced during insulin
infusion at the frontal, parietal, and central location
with the frontal location showing the greatest amp-
litude changes, whereas the central and parietal
locations were reduced only within 500 ms of the
stimulus presentation. The results of these studies
are similar to those obtained previously by the
same groups using the hyperinsulinemic/euglycemic
clamp, for which insulin levels are kept elevated
while glucose levels are kept at fasting levels
through intravenous glucose infusion (Kern et al.,
1998) or during insulin-induced hypoglycemia
(Kern et al., 1990. Tamburrano et al., 1988).
The results of these studies suggest that insulin
itself is the cause of the observed neuroelectric
changes. Another study used the hyperinsulinemic/
euglycemic clamp to study the effect of low and
high levels of blood insulin on evoked brain
potentials, as well as on neuropsychological
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revealed no difference between the N1 and P2
components elicited during the presentation of
frequent tones under low and high insulin levels.
An increase in P3 latency at the frontal and
parietal placement was observed but, contrary to
the intranasal study, no clear baseline-to-peak P3
amplitude increase. There was an increase in slow
wave in the frontal regions during the high insulin
condition and a small increase in the number of
emotional and food-related words recalled toward
the end of the 6 h of testing, which was concurrent
with an increase of correct responses during the
interference condition of the Stroop test and
increases in the feeling ofhunger.
Lastly, an experiment examined the effect of 8
weeks of intranasal insulin on cognitive
performance and mood (Benedict et al., 2004). A
40IU insulin dose was infused into the nose 4
times a day. The participants were first tested
during the placebo phase of the trial, after the
infusion of the first insulin solution, and week
before the end of the trial. No difference was
found between the per-formance of the insulin and
saline groups for memory, except for delayed
recall of words tested week after the last testing
session. Furthermore, no effect of insulin on the
Stroop test or on word stem completion was found.
There were, however, increases in the self-rating
mood scores for self-confidence and well-being,
as well as a reduced self-rating of depression after
receiving insulin for 8 weeks (Benedict et al.,
2004). Finally, one recent trial showed that
intranasal insulin (20 IU) im-proved declarative
memory in Alzheimer’s patients and, to a lesser
degree, in older adults (Baker et al., 2003).
In summary, studies that examined the effect
of the hyperinsulinic clamp on cognitive function
found a small but consistent improvement in
memory and changes in brain neuroelectric para-
meters in evoked brain potentials, consistent with
improved attention or memory processing. One
PET study using the hyperinsulinemic/euglycemic
clamp showed that brain glucose uptake increased
during that procedure, suggesting that this increase
may underlie the effect of the clamp procedure on
brain functions. Studies using intra-nasal insulin
reported cognitive improvements similar to those
described with the hyperinsulin-emic clamp,
suggesting that the effects of this procedure are
likely due to increased brain insulin levels.
The final sections of this review deals with the
possible interaction between the brain’s insulin
and IGF-I signaling pathways, as well as their
possible role in brain aging and Alzheimer’s
disease. The literature on insulin growth factors
and their roles in development and brain maturing
is extensive and will not be reviewed here except
for a brief presentation of key facts. The reader is
referred to the comprehensive review by Juul
(2003) for an exhaustive overview of IGF-I roles,
physiology, and biochemistry.
INSULIN AND INSULIN GROWTH FACTOR-1
Insulin, insulin growth factor (IGF-I) and
insulin growth factor 2 (IGF-II) are ubiquitous
molecules that have important roles in maintaining
homeostasis, in postnatal growth, and in develop-
ment (Juul, 2003). Insulin, IGF-I, and IGF-II each
has its own receptor but cross-interact with low
affinity with each others’ receptors. In blood,
insulin is found in picomolar concentrations
whereas IGF-I is found in nanomolar concentra-
tions. In theory, this would lead to a much higher
impact of IGF-I on all three receptors if not for the
finding that much of the IGF is bound to IGF
binding proteins (IGFBP-3) in the blood, which
blocks its biological activity (Baxter et al., 1998).
Both IGF-I and IGFBP-3 decrease monotonically
after puberty (Juul et al., 1994).
Insulin and IGF-I are genetically related
polypeptides that share substantial amino acid
sequences. Although insulin is synthesized in the
pancreas, IGF-I is produced by the liver, and its
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hormone. IGF-I is also synthesized in the brain,
where growth hormone does not influence its
expression (Bondy & Cheng 2004). In rats, the
expression of mRNA for IGF-I is maximal during
development of the nervous system but remains
expressed in the adult brain in many regions
including the hippocampus, olfactory bulb,
hypothalamic area, and cerebellum, as well as in
epithelial and ependymal cells of the choroids
plexus (Rotwein et al., 1990).
Overexpression of IGF-I in transgenic animals
results in increased brain size and myelination
(Carson et al., 1993), whereas IGF-I knockout
animals have smaller brains, a smaller granule cell
layer in the dentate gyrus, and lower numbers of
oligodendrocytes and myelinated axons (Beck et
al., 2004). The role of IGF-I is also illustrated by a
recent report showing that when weaver mutant
mice, who exhibit apoptosis of cerebellar granule
neurons, are cross-bred with transgenic mice
overexpressing IGF-I, an increase in surviving
granule cells and a decrease in apoptotic cells
reduced the impact of the weaver mutation (Zhong
et al., 2005). IGF-I transgenic animals were also
shown to have greater number of synapses during
and after post-natal development (O’Kusky et al.,
2000. 003).
Another series of experiments ex-amined the
effect of IGF-I on cell differentiation in
multipotent adult neural progenitor cells and found
that IGF-I played an instructive role by shifting the
differentiation process from the production of
astrocytes to oligodendrocytes and, to a lesser
extent, neurons (Hsieh et al., 2004). This effect
was thought to be dependent on the indirect
inhibition of the bone morphogenetic protein
(BMP) signaling by the upregulation of BMP
antagonists Noggin, Smad6, and Smad7.
Although much remains to be done in
elucidating the role of IGF-I using transgenic
animals, the general view is that IGF-I controls
and/or enables the growth of new brain cells
including neurons and glia, reduces developmental
apoptosis, and increases synaptogenesis during early
post-natal development (D’Ercole et al., 2002).
A number of observations have led researchers
to study the role of IGF-I in aging and dementia. In
a small study, it was found that IGF-I blood levels
are correlated with MMSE performance in older
persons (65 years and over), with lower levels of
IGF-I being associated with lower performance in
the MMSE (Rollero et al., 1998). Plasma insulin-
like growth factor I (IGF-I) level was reduced in
family members carrying the Swedish amyloid
precursor protein (APP) 670/671 mutation with
Alzheimer’s disease (AD) compared with age-
matched controls from the same family carrier
withoutAD (Mustafa et al., 1999).
Also, IDDM and severe insulin resistance may
cause acquired IGF-I resistance through a decrease
in IGF-I availability or altered second messenger
systems (Jain et al., 1998). Studies in patients with
diabetes have shown that in insulin-deficient states,
serum IGF-I concentrations are low and increase
with insulin therapy (Bereket et al., 1996). Although
total IGF-I has been found to be within normal
values in type 2 diabetes, free IGF-I remains
elevated in type 2 diabetic patients to a degree
similar to that observed in obese individuals without
diabetes (Frystyk et al., 1999). In normal subjects,
low IGF-I is associated with high 2-h glucose
concentrations during a glucose tolerance test
(Sandhu et al., 2002), indicating that IGF-I has a
role in peripheral uptake of glucose.
Studies conducted in experimental animals have
shown that if IGF-I synthesis by the liver is stopped,
the animals become insulin-resistant, and this
situation is improved when IGF-I is administered.
Likewise, deletion of the IGF-I receptor in muscle
tissue in mice induces severe insulin resistance. The
administration of IGF-I to patients with type 2
diabetes mellitus has been shown to result in an
improvement in insulin sensitivity and a reduction
in the requirement for exogenously administered
insulin to maintain glucose homeostasis
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In summary, IGF-I is involved in brain
development and maturation. Peripheral levels are
associated with peripheral glucose regulation and
interact with insulin mechanisms that control
glucose disposal. In the next section, we briefly
review the results of studies that have examined
the impact of insulin and IGF-I on amyloid
production and disposal in animal models and in
patients with Alzheimer’s disease.
INSULIN AND IGF-I AND AMYLOID
ACCUMULATION
Beta-amyloid (AI3) is a potemially deleterious
compound when it accumulates in the aging brain
and is associated with Alzheimer’s disease (Selkoe,
2001). During aging, IGF-I levels decline, with a
decreased sensitivity to insulin and IGF-I as well
(Jain et al., 1998). Both hormones are presumed to
help reduce beta-amyloid toxicity by increasing its
cellular release (Gasparini et al., 2001), stimulating
tissue clearance (Carro et al., 2002), and protecting
from its toxic effects (Niikura et al., 2001).
Previous experiments had shown an increased
uptake of insulin at the blood brain barrier of the
Tg2576 (double transgenic APP and PSI) mouse
(Poduslo et al., 2001) and when fed a high-
cholesterol diet for 7 weeks, an increased amyloid
load and deposit size in the Tg2576 mouse (Refolo
et al., 2000). In a more recent experiment, Tg2576
mice were given access to a 60% fat diet and it
was found that the diet induced insulin resistance,
higher weight, and higher evoked blood glucose
levels, but no change in total cholesterol occurred
compared with standard-chow-fed animals (Ho et
al., 2004).
However, a 5-month exposure to the diet
doubled the amount of AI3-40 and AI342 and also
increased the number and volume of 6E10-
immunopositive amyloid plaques. The high-fat diet
also reduced markers of insulin receptor activity
(PI3K, AKT/PKB, and Glycogen synthase kinase-
3. [GSK-3t]), consistent with insulin resistance
and reduced performance in the water maze.
Finally, the high-fat diet also reduced IDE
expression and activity.
On the other hand, the inhibition of GSK-3t
by lithium chloride has been shown to decrease the
production of amyloid peptides in animal models
of Alzheimer’s disease (Phiel et al., 2003), which
would suggest that higher insulin receptor activity
leads to higher amyloid production. In cell
cultures, it was shown that insulin decreases
intracellular levels of A1340 and AI342, which
appeared to be mediated by an accelerated transfer
from the Golgi/transGolgi net-work to the plasma
membrane (Gasparini et al., 2001).
There is now good evidence that insulin-
degrading enzyme (IDE) is one of the proteins that
degrades beta-amyloid in vivo and in vitro and is
selective for the AI3 monomer (Farris et al., 2003.
Vekrellis et al., 2000). Additionally, a number of
linkage studies have identified chromosome 10q as
a site of a number of markers for increased plasma
levels of beta amyloid that are close to the IDE site
(Bertram et al., 2000. Ertekin-Taner et al., 2000,
2004. Prince et al., 2003), although a number of
genetic studies concluded that IDE was not
associated with late-onset Alzheimer’s disease
(Abraham et al., 2001. Boussaha et al., 2002).
Two recent studies suggested that IDE variant
expres-sion may affect Alzheimer’s severity rather
than risk (Blomqvist et al., 2005), and there may
be inefficient forms of IDE that foster poor
amyloid processing (Farris et al., 2005). Some
post-mortem studies have also indicated that
hippocampal IDE levels and mRNA were
decreased in AD brain tissue from patients with
the APOE4 gene (Cook et al., 2003).
Using the Brain Efflux Index, a study showed
that AI3 (1-40) elimination from the brain was
reduced by 30% in old rats, whereas inhibitors of
neprilysin and IDE (the two main amyloid-
degrading enzymes) reduced AI3 efflux by 25% to
30% (Shiiki et al., 2004). Neprilysin knockoutINSULIN AND GLUCOSE TRANSPORTERS 321
mice have a two-fold increase in AI3 (1-40) and
AI3 (1-42) in the brain (Iwata et al., 2000), but a
34% inhibition of AI3-elimination rate by
thiorphan, a neprilysin inhibitor, suggests that
neprilysin action is non-saturable or that AI
fragments inhibit their efflux transport (Shiiki et
al., 2004). In the same study, the co-administration
of insulin with AI3 (1-40) reduced the elimination
rate of AI (1-40) and increased the level of intact
AI3 (1-40) in the brain (Shiiki et al., 2004). The
results of that study parallel those obtained in
humans, in which systemic insulin infusions led to
an increase in CSF AI3 (1-42) (Watson et al.,
2003). One possibility is that insulin competes
with AI3 (1-40) (Xie et al., 2002) for transcytosis
transport using the insulin receptor at the BBB
(Pardridge et al., 1995). However, an inhibitor of
the insulin receptor kinase failed to affect AI3
elimination rate (Shiiki et al., 2004).
Another experiment using hippocampal cell
cultures showed that treatment with insulin pro-
duced an increase in IDE-protein levels, which
was accompanied by an increase in phosphadyl-
inositol-3 (PI-3) (Zhao et al., 2004). The inhibition
of PI-3 abolished the upregulation of IDE by
insulin, suggesting that the effect of insulin on IDE
may be mediated through an activation of the
insulin receptor. The authors also showed that in
Tg2576 mice raised on a safflower oil-based diet,
a reduction in IDE mRNA and protein expression
correlated with the level of beta-amyloid in the
hippocampus.
Finally, a post-mortem study showed reduced
IDE levels in the hippocampus and temporal
cortex of Alzheimer’s patients, and the highest
reductions were found in patients with two copies
of the ApoE4 allele (Zhao et al., 2004).
Additionally, levels of IDE and neprilysin were
found to be lower in the human hippocampus and
cortex compared with levels in the cerebellum, a
structure having fewer amyloid deposits in AD
(Caccamo et al., 2005). The same study also found
that 75% of IDE was oxidized in the AD hippo-
campus compared with 25% in the cerebellum,
suggesting the possibility that the enzymatic
activity of oxidized IDE may be reduced, leading
to increased amyloid deposition (Caccamo et al.,
2005). This result is consistent with the observation
that in transgenic mice overexpressing APP, AI3-
amyloid deposition increases in a progressive, age-
related fashion, despite the presence of high APP
levels throughout their lifetime. Taken together,
the results of these studies support the hypothesis
that amyloid accumulation in the aging brain is
due to deficits in degradation rather than to an
increase in amyloid production, and that brain
insulin, insulin receptor activity, or the insulin
degrading enzyme play a role in the clearance of
AI3 amyloid.
GENERAL CONCLUSIONS
Brain insulin, most of which comes from the
pancreas, is taken up by the brain by what appears
to be a receptor-based carrier. Insulin is transported
at various rates through the blood-brain barrier to
different brain regions.
Type 2 diabetes animal models associated with
insulin resistance show reduced insulin brain uptake
and content. Some recent data point to changes in
the insulin receptor cascade in obesity-related
insulin resistance, which is consistent with a
reduced sensitivity of insulin receptors. Such
changes are accompanied by reductions in synaptic
plasticity. The absence of insulin receptors in the
brain of conditional knockout mice does not reveal
any major deficit in learning and memory,
suggesting that insulin and insulin receptors have
modulatory roles, or that compensatory
mechanisms exist.
Insulin transport to the brain is reduced in
aging and in some animal models of type 2
diabetes. Because brain- insulin uptake is receptor
based, insulin resistance would thus lead to a
reduction in both insulin uptake and the ability of322 C. MESSIERAND K. TEUTENBERG
insulin to stimulate its receptors in the brain.
Studies examining the effect of the hyper-
insulinic clamp or intranasal insulin on cognitive
function have found a small but consistent im-
provement in memory and changes in brain
neuroelectric parameters in evoked brain potentials.
These changes are consistent with improved atten-
tion or memory processing. These effects appear to
be due to raised brain insulin levels. The results
also suggest that a reduction in brain insulin or
brain insulin sensitivity could be the cause ofsome
of the cognitive deficits observed in persons with
impaired glucose tolerance or type 2 diabetes.
Insulin growth factor-I is involved in brain
development and maturation. Peripheral levels are
associated with peripheral glucose regulation and
interact with insulin mechanisms that control
glucose disposal. There is some indication that
decreased sensitivity to insulin or to IGF-I as
observed in aging, obesity, and diabetes decreases
the clearance of A[3 amyloid through processes
that appear to involve the insulin receptor.
However, the exact sequence of cellular events for
these processes remains to be elucidated. Insulin
and IGF-I also appear to modulate the brain levels
of insulin degrading enzyme. This enzyme has
been shown to be important in the degradation of
insulin and a reduction of its activity would lead to
accumulation of A[3 amyloid. This hypothesis is
consistent with the observation that amyloid
deposition is increased both in transgenic animal
models of Alzheimer’s disease that are diabetic
and in diabetic patients suffering from Alzheimer’s
disease.
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